Pheng Bora

Pheng Bora Professional Medical Doctor
Specialist in Cancer, Blood Diseases, Cellular Therapy and Immunology, stem cell, anti aging, holistic wellness Cancer.

វិទ្យាសាស្ត្រចេះតែវិវត្តិទៅមុខ ក្តីសង្ឃឹមថ្មីចេះតែមានឡើងសម្រាប់អ្នកជម្ងឺមហារីកសួត ដែលធ្លាប់តែមិនសូវមានថ្នាំព្យាបាល 😍
05/07/2025

វិទ្យាសាស្ត្រចេះតែវិវត្តិទៅមុខ ក្តីសង្ឃឹមថ្មីចេះតែមានឡើងសម្រាប់អ្នកជម្ងឺមហារីកសួត ដែលធ្លាប់តែមិនសូវមានថ្នាំព្យាបាល 😍

01/07/2025

ADVANTAGES OF LEUCOCYTE REDUCTION FILTER FOR BEDSIDE



1. Residential WBC count less than 1*10E6/ Unit (Removal rate of leukocytes is 99%)
2. Decrease the cost of medical care by diminish the role leukocytes play in mediating adverse reactions to transfusion include the lower risk of non-hemolytic febrile transfusion reaction (NHFTR) and protection patient against leukocyte related transfusion
3. Reduce HLA Alloimmunization, risk of transfusion associated graft v/s host disease (GVHD), Human T-Lymphotropic virus (HTLV), and reactivation of intracellular virus (Cytomegalovirus…)




សារះប្រយោជន៍នៃការប្រើប្រាស់ឧបករណ៍ចម្រោះគ្រាប់ឈាមស សម្រាប់អ្នកជម្ងឺ

1. បន្សល់ទុកកោសិកាគ្រាប់ឈាមស តិចជាង 1*10E6/​​​​​​​ Unit​ ក្រោយពេលឆ្លងកាត់ការចម្រោះ​ (អត្រានៃការច្រោះគ្រាប់ឈាម​ស រហូតដល់ ៩៩%)
2. ជួយកាត់បន្ថយការចំណាយផ្នែកការថែរទាំវេជ្ជសាស្ត្រ ដោយទប់ទល់ផលរំខានដោយសារគា្រប់ឈាម​ស នៅពេលធ្វើការបញ្ចូលឈាមរួមមាន ការថយចុះនូវការប្រឈមមុខនិង non-hemolytic febrile transfusion reaction (NHFTR)​ នឹង​ ការពារអ្នកជម្ងឺពីហានិភ័យផ្សេងៗដែលទាក់ទងនិងគ្រាប់ឈាមស រាល់ពេលបញ្ចូលឈាមម្តងៗ
3. កាត់បន្ថយ ​
a. ការបង្កើតអង់ទីករប្រឆាំងនិងកោសិកាដទៃ ដោយការសិការ Human Leukocyte Antigen (HLA Alloimmunization)
b. គ្រោះថ្នាក់ក្នុងការបញ្ចូលឈាមដោយសារអង់ទីករអ្នកផ្តល់ប្រឆាំងនឹងអ្នកទទួល (Graft v/s Host Disease)
c. វីរុស Human T-Lymphotropic, ពិសេសការធ្វើអោយមានសកម្មភាពឡើងវិញនៅវិរុសនៅក្នុងកោសិកា ដូចជា វីរុស Cytomegalovirus…

09/03/2025
09/03/2025

ឈាមពណ៌ដូចទឹកដោះគោ ដោយសារលើសឈាមសច្រើន
ព្យាបាលដោយដកច្រោះឈាមសចេញពីខ្លួនអ្នកជម្ងឺ
White Blood Cell Depletion

Congratulations 🎉 to this patient from Malaysia that have been cured from Transfusions Dependent Thalassemia (TDT) by us...
23/01/2025

Congratulations 🎉 to this patient from Malaysia that have been cured from Transfusions Dependent Thalassemia (TDT) by using Gene Therapy 🤩💪

PROSTATE CANCER: WHAT EVERY MAN SHOULD KNOWProstate cancer is the second most common cancer in men.Why is it so common?W...
10/01/2025

PROSTATE CANCER: WHAT EVERY MAN SHOULD KNOW
Prostate cancer is the second most common cancer in men.
Why is it so common?
When should you be concerned?
Let’s learn everything about prostate cancer, and how to reduce your risk of developing it.
WHAT IS THE PROSTATE, AND WHY DOES IT MATTER?
The prostate is a small gland in the male reproductive system, just about the size of a walnut.
What does it do?
It produces a fluid that nourishes and protects the s***m.
The fluid mixes with s***m to form semen, which is vital for fertility.
WHAT IS PROSTATE CANCER?
Prostate cancer occurs when the cells in the prostate gland begin to grow uncontrollably.
They may form tumors that can stay in the prostate or spread to other areas like the bones, lymph nodes and lungs.
There’re 2 main types:
- Slow growing prostate cancer
- Aggressive prostate cancer
Slow growing cancers may not cause symptoms for years, and requires little or no treatment.
Aggressive prostate cancer grows very fast, spreads quickly, and requires immediate attention.
WHO IS AT RISK?
Certain factors increase your risk of developing prostate cancer. They include:
- Age: The older a man gets, the more likely he is to develop prostate cancer.
It rises significantly after 50, and most cases are diagnosed after 65.
- Family history: Your risk of developing it increases, if your father, brother or close relative had it.
- Race: African men have a higher risk of developing aggressive forms of prostate cancer.
- Lifestyle factors: An unhealthy diet, sedentary lifestyle and bad vices over time increases your risk of developing prostate cancer.
- Genetic mutations: Mutations in BRCA 1&2 genes increases your risk.
BRCA genes are tumor suppressor genes and mutations or changes predispose you to cancer.
WHEN SHOULD YOU BE CONCERNED?
Prostate cancer develops silently, especially in its early stages.
However, as it progresses, symptoms include:
- Difficulty starting or stopping urination
- Weak or interrupted urine stream
- Frequent urination, especially at night
- Blood in urine or semen
- Pain or stiffness in the lower back, hips, or pelvis.
HOW IS IT DIAGNOSED?
Diagnosis is usually a combination of:
- PSA (Prostate-specific antigen) blood test: Elevated PSA levels may indicate prostate cancer, or benign prostatic hyperplasia.
- Digital re**al examination: A doctor checks the prostate for lumps or abnormalities.
- Biopsy: If cancer is suspected, a small tissue sample is taken from the prostate and examined for confirmation.
MRIs or CT scans can be used to check if cancer has spread to other areas.

09/01/2025

Here are definitions and comparisons for each imaging modality:

*1. X-Ray*

- Definition: Uses ionizing radiation to produce images of internal structures.
- Principle: X-rays pass through body, absorbed by dense materials (bones), and detected.
- Uses: Bone fractures, lung diseases, foreign objects.

*2. MRA (Magnetic Resonance Angiography)*

- Definition: Non-invasive imaging of blood vessels using MRI technology.
- Principle: Magnetic fields and radio waves visualize blood flow.
- Uses: Vascular diseases, aneurysms, stenosis.

*3. MRI (Magnetic Resonance Imaging)*

- Definition: Non-invasive imaging using magnetic fields and radio waves.
- Principle: Hydrogen atoms align, emitting signals, creating detailed images.
- Uses: Soft tissue injuries, tumors, neurological disorders.

*4. PET (Positron Emission Tomography) Scan*

- Definition: Functional imaging assessing metabolic activity.
- Principle: Radioactive tracers emit positrons, detected by scanner.
- Uses: Cancer diagnosis/staging, brain disorders, cardiovascular disease.

*5. CT (Computed Tomography) Scan*

- Definition: Imaging using X-rays and computer reconstruction.
- Principle: X-rays pass through body, detected, and reconstructed into images.
- Uses: Trauma, cancer, vascular diseases, internal injuries.

ROSTATE CANCER: WHAT EVERY MAN SHOULD KNOWProstate cancer is the second most common cancer in men.Why is it so common?Wh...
07/01/2025

ROSTATE CANCER: WHAT EVERY MAN SHOULD KNOW

Prostate cancer is the second most common cancer in men.

Why is it so common?
When should you be concerned?

Let’s learn everything about prostate cancer, and how to reduce your risk of developing it.

WHAT IS THE PROSTATE, AND WHY DOES IT MATTER?

The prostate is a small gland in the male reproductive system, just about the size of a walnut.

What does it do?

It produces a fluid that nourishes and protects the s***m.

The fluid mixes with s***m to form semen, which is vital for fertility.

WHAT IS PROSTATE CANCER?

Prostate cancer occurs when the cells in the prostate gland begin to grow uncontrollably.

They may form tumors that can stay in the prostate or spread to other areas like the bones, lymph nodes and lungs.

There’re 2 main types:
- Slow growing prostate cancer
- Aggressive prostate cancer

Slow growing cancers may not cause symptoms for years, and requires little or no treatment.

Aggressive prostate cancer grows very fast, spreads quickly, and requires immediate attention.

WHO IS AT RISK?

Certain factors increase your risk of developing prostate cancer. They include:

- Age: The older a man gets, the more likely he is to develop prostate cancer.

It rises significantly after 50, and most cases are diagnosed after 65.

- Family history: Your risk of developing it increases, if your father, brother or close relative had it.

- Race: African men have a higher risk of developing aggressive forms of prostate cancer.

- Lifestyle factors: An unhealthy diet, sedentary lifestyle and bad vices over time increases your risk of developing prostate cancer.

- Genetic mutations: Mutations in BRCA 1&2 genes increases your risk.

BRCA genes are tumor suppressor genes and mutations or changes predispose you to cancer.

WHEN SHOULD YOU BE CONCERNED?

Prostate cancer develops silently, especially in its early stages.

However, as it progresses, symptoms include:

- Difficulty starting or stopping urination
- Weak or interrupted urine stream
- Frequent urination, especially at night
- Blood in urine or semen
- Pain or stiffness in the lower back, hips, or pelvis.

HOW IS IT DIAGNOSED?

Diagnosis is usually a combination of:

- PSA (Prostate-specific antigen) blood test: Elevated PSA levels may indicate prostate cancer, or benign prostatic hyperplasia.

- Digital re**al examination: A doctor checks the prostate for lumps or abnormalities.

- Biopsy: If cancer is suspected, a small tissue sample is taken from the prostate and examined for confirmation.

MRIs or CT scans can be used to check if cancer has spread to other areas.

07/01/2025

Historically considered a lymphoma with limited treatment options and poor outcomes, the treatment landscape in mantle cell lymphoma (MCL) has evolved remarkably in the last decade. Chemoimmunotherapy (CIT) remains the primary frontline treatment for most patients with MCL, typically with an intensive approach in younger and fit patients. The role of consolidative autologous stem cell transplantation remains controversial, with recent data further questioning its benefit. Novel agents have shown promising results in recent frontline clinical trials and challenge the current paradigm in MCL, particularly in high-risk patients who generally have poor outcomes with CIT. Risk stratification is key to incorporating novel agents in the frontline treatment of MCL, identifying patients who do not benefit from or could be spared CIT, guiding treatment intensity and duration, and improving overall outcomes, including safety and quality of life. The MCL International Prognostic Index and Ki-67 play an important role in identifying patients with high-risk MCL. TP53 aberrations, particularly mutations, currently identify patients with the highest risk, limited benefit from CIT, and greatest need for novel therapies. Other genetic aberrations and biological clusters are being identified but currently have limited clinical utility.

អបអរសាទរ ខួបលើកទី ៤៦ ឆ្នាំ នៃទិវាជ័យជំនះ ៧ មករា៧មករា ១៩៧៩ - ៧ មករា ២០២៥៧ មករា ជាថ្ងៃរំដោះនិងសង្រ្គោះប្រទេសជាតិបានរួចផុតព...
07/01/2025

អបអរសាទរ ខួបលើកទី ៤៦ ឆ្នាំ នៃទិវាជ័យជំនះ ៧ មករា
៧មករា ១៩៧៩ - ៧ មករា ២០២៥

៧ មករា ជាថ្ងៃរំដោះនិងសង្រ្គោះប្រទេសជាតិបានរួចផុតពីរបបប្រល័យពូជសាសន៍ប៉ុលពតពិតប្រាកដ។
៧ មករា គឺជាកំណើតទី២ នៃពលរដ្ឋខ្មែរ និងជាដើមកំណើតនៃសន្តិភាពពិតប្រាកដសម្រាប់កម្ពុជាទាំងមូល។

រួមគ្នាថែរក្សា ការពារសន្តិភាព សម្រាប់ប្រទេសជាតិយើង។

អរគុណសន្តិភាព!

The combination of decitabine, venetoclax, and ponatinib is a safe option with promise for patients with advanced phase ...
05/01/2025

The combination of decitabine, venetoclax, and ponatinib is a safe option with promise for patients with advanced phase chronic myeloid leukemia (CML), even among those with extensive prior treatments or high-risk disease characteristics. Read more and pursue CME credits:

An abstract is unavailable.

Address

Phnom Penh

Telephone

+85578666990

Website

Alerts

Be the first to know and let us send you an email when Pheng Bora posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Pheng Bora:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram